MedTrace Logo

A Study of KC1036 in Patients with Advanced Thymic Tumors

NCT05683886 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-10-17

No results posted yet for this study

Summary

This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.

Conditions

  • Thymic Tumors

Interventions

DRUG

KC1036

Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.

Sponsors & Collaborators

  • Beijing Konruns Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yongsheng Wang, Ph.D · West China Hospital

  • Wentao Fang, Ph.D · Shanghai Chest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-22
Primary Completion
2025-02-28
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05683886 on ClinicalTrials.gov